PharmaCyte Biotech on Track to Commence Clinical Trials

SILVER SPRING, Md., March 27, 2015 (GLOBE NEWSWIRE) -- PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials.

The cells being produced came from a fully characterized single-cell clone of the cells that were used in the previous clinical trials in pancreatic cancer. These cells are being grown under conditions that comply with current Good Manufacturing Practices (cGMP) standards.

One of PharmaCyte Biotech's clinical trials consists of a Phase 2b trial where PharmaCyte Biotech's pancreatic cancer treatment will be compared "head-to-head" with the best available chemotherapy (Abraxane® plus gemcitabine) for advanced pancreatic cancer. The Phase 2b...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.